

Symposium – Update in Hereditary Angioedema: A Disease in Rapid Evolution

Supported by an educational grant from Dyax Corporation.

2008 Annual Meeting Webcast

Objectives: Upon completions of this session, participants should be able to: 1) discuss the pathogenesis and types of angioedema; 2) discuss the pathogenesis and types of hereditary angioedema; 3) describe clinical presentations of patients with hereditary angioedema; 4) discuss the diagnosis of patients with hereditary angioedema; 5) review importance of angioedema etiology in guiding choice of therapy; 6) discuss current treatment of hereditary angioedema; and 7) discuss emerging treatments for hereditary angioedema.

- ❶ Speaker Evaluation—Please evaluate only those speakers you have heard according to the following scale:
(1 = poor; 2 = fair; 3 = good; 4 = excellent)

<i>Speaker/Topic</i>	<i>Met Objectives</i>	<i>Content</i>	<i>Effectiveness of Teaching/Learning Methods</i>	<i>Interest of Topic</i>	<i>Applicability to Your Practice</i>	<i>Quality of AV Material</i>	<i>Bias?</i>	<i>Invite Again?</i>	<i>For office use only</i>
Types & Pathogenesis Mark S. Dykewicz, MD							<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	045
Hereditary Angioedema Manifestations.... Alcena Banerji, MD							<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	046
Current and New Therapies Mark A. Riedl, MD							<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	047

- ❷ Overall Evaluation of Importance of Session (4 = very; 3 = moderate; 2 = little; 1 = not at all) _____

- ❸ Do you intend to make any changes in your practice as a result of this activity? Yes _____ No _____

If **Yes**, how? Comment _____

- ❹ Did the speaker(s) make proper disclosure of potential conflict of interest, and clarification to audience of faculty relationship with industry and nature of that relationship? Yes _____ No _____

- ❺ Did you perceive industry bias for or against commercial product(s), services, or commercial supporter of this activity?
Yes _____ No _____ If **Yes**, please comment; e.g., scientific balance, objectivity, etc.

Comment _____

- ❻ Did the speaker(s) disclose with respect to FDA Off-Label use? Yes _____ No _____

If **NO**, please comment _____

- ❼ What related topics should be addressed at future ACAAI meetings? _____

- ❽ Comments:

- ❾ Name (please print) optional: _____

**Please submit this Evaluation and Test Results to the American College of Allergy, Asthma & Immunology
85 W. Algonquin Rd., #550, Arlington Heights, IL 60005 -- Fax (847) 427-1294**

2008 Annual Meeting Webcast Assessment
Update in Hereditary Angioedema: A Disease in Rapid Evolution

Please circle the correct answer

- 1) The main cause of hereditary angioedema is?
 - a. Histamine
 - b. Complement
 - c. Bradykinin
 - d. Estrogen
 - e. Unknown cause

- 2) During an attack of HAE the protein that decreases is?
 - a. C-1
 - b. C-3
 - c. C-4
 - d. C-5
 - e. C-9

- 3) The test or assay for HAE that is not very reliable in the USA is?
 - a. C-4
 - b. C-1
 - c. C-2
 - d. C-1-INH protein
 - e. C-1-INH functional

- 4) Which product is effective for acute attacks of HAE?
 - a. Androgens
 - b. Antihistamines
 - c. Corticosteroids
 - d. Fresh Frozen Plasma
 - e. Adrenaline

- 5) The products that are in development for HAE include all except?
 - a. Frankinase
 - b. Icatibant
 - c. Ecallantide
 - d. C-1-esterase Inhibitor
 - e. Recombinant C-1-INH

- 6) C-1-esterase inhibitor concentrate inhibits the products below except?
 - a. C-1rs activation of C-4
 - b. Plasminogen to plasmin
 - c. C3 to C5
 - d. Prekallikrein to kallikrein
 - e. High molecular weight kinninogen to bradykinin

Name: _____ E-mail: _____

Address: _____

Telephone #: _____ Fax #: _____

Please submit the evaluation and assessment to:
ACAAI – 85 W. Algonquin Rd., #550, Arlington Heights, IL 60005 Fax: 847-427-1294